Friday, 16 October 2026European Markets

GOLDEN OCEAN GROUP And VEIDEKKE Have A High Dividend Yield And Return On Equity In The Industrials Sector.

Loading stream...

(VIANEWS) - GOLDEN OCEAN GROUP (GOGL.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Industrials sector.

Financial Asset Price Forward Dividend Yield Return on Equity
GOLDEN OCEAN GROUP (GOGL.OL) kr77.36 9.87% 10.43%
VEIDEKKE (VEI.OL) kr99.80 7.82% 50.8%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. GOLDEN OCEAN GROUP (GOGL.OL)

9.87% Forward Dividend Yield and 10.43% Return On Equity

Golden Ocean Group Limited, a shipping company, owns and operates a fleet of dry bulk vessels worldwide. It operates dry bulk vessels comprising of Newcastlemax, Capesize, Panamax, and Ultramax vessels in the spot and time charter markets. The company's vessels transport a range of bulk commodities, such as ores, coal, grains, and fertilizers. As of March 16, 2023, it owned a fleet of 74 dry bulk vessels. The company is based in Hamilton, Bermuda.

Earnings Per Share

As for profitability, GOLDEN OCEAN GROUP has a trailing twelve months EPS of kr10.5.

PE Ratio

GOLDEN OCEAN GROUP has a trailing twelve months price to earnings ratio of 7.37. Meaning, the purchaser of the share is investing kr7.37 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.43%.

Yearly Top and Bottom Value

GOLDEN OCEAN GROUP's stock is valued at kr77.36 at 22:30 EST, way below its 52-week high of kr111.10 and above its 52-week low of kr71.04.

Volume

Today's last reported volume for GOLDEN OCEAN GROUP is 399878 which is 21.14% below its average volume of 507135.

More news about GOLDEN OCEAN GROUP.

2. VEIDEKKE (VEI.OL)

7.82% Forward Dividend Yield and 50.8% Return On Equity

Veidekke ASA operates as a construction and property development company. It operates through Construction Norway, Infrastructure Norway, Construction Sweden, Infrastructure Sweden, and Denmark/Hoffmann segments. The company operates as a construction contractor; executes civil engineering and renovation projects; and produces asphalt and aggregates, as well as operates in the public road maintenance market. It is also involved in the civil engineering, recycling, and asphalting projects, as well as constructs commercial and residential buildings. Veidekke ASA was founded in 1936 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, VEIDEKKE has a trailing twelve months EPS of kr7.7.

PE Ratio

VEIDEKKE has a trailing twelve months price to earnings ratio of 12.96. Meaning, the purchaser of the share is investing kr12.96 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 50.8%.

Volatility

VEIDEKKE's last week, last month's, and last quarter's current intraday variation average was a negative 0.38%, a negative 0.53%, and a positive 1.03%.

VEIDEKKE's highest amplitude of average volatility was 0.88% (last week), 1.22% (last month), and 1.03% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VEIDEKKE's stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

VEIDEKKE's EBITDA is 0.31.

More news about VEIDEKKE.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com